Complementary, selective PET imaging of integrin subtypes α5β1 and αvβ3 using 68Ga-aquibeprin and 68Ga-avebetrin

Journal of Nuclear Medicine

Volumn 57, Issue 3, 2016, Pages 460-466

  Notni, Johannes ^a   Steiger, Katja ^a   Hoffmann, Frauke ^a   Reich, Dominik ^a   Kapp, Tobias G ^a   Rechenmacher, Florian ^a   Neubauer, Stefanie ^a   Kessler, Horst ^a   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

68Ga; Angiogenesis; Immunohistochemistry; Integrins; Positron emission tomography

Indexed keywords

AQUIBEPRIN GA 68; AVEBETRIN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; 68GA-AQUIBEPRIN; 68GA-AVEBETRIN; COORDINATION COMPOUND; PARAFFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CLICK CHEMISTRY; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; HYDROPHILICITY; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; URINARY EXCRETION; ANIMAL; BINDING COMPETITION; BIOSYNTHESIS; CANCER TRANSPLANTATION; ENZYME SPECIFICITY; EXPERIMENTAL NEOPLASM; METABOLISM; MUSCLE; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; COORDINATION COMPLEXES; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; MICE; MUSCLES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PARAFFIN EMBEDDING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84960156835     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.165720     Document Type: Article

References (40)

1. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol. 2011;23: 607-614.
2. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8: 604-617.
3. Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent antiangiogenic drugs. Expert Opin Investig Drugs. 2012;21: 451-472.
4. Seystahl K, Weller M. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin Investig Drugs. 2012;21: 605-617.
5. Dijkgraaf I, Boermann OC. Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24: 637-647.
6. Brooks PC, Clark R, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264: 569-571.
7. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67: 5064-5066.
8. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin avb3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96: 1815-1822.
9. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155: 459-470.
10. Brooks PC, Montgomery AMP, Rosenfeld M, et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79: 1157-1164.
11. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123: 3190-3200.
12. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg- Gly-Asp constrained within cyclic pentapeptides: Strong and selective inhibitors of cell-adhesion to vitronectin and laminin fragment-P1. FEBS Lett. 1991;291: 50-54.
13. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des. 2006;12: 2723-2747.
14. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping avb3- integrin expression in vivo. Acc Chem Res. 2009;42: 969-980.
15. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled avb3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med. 1999;40: 1061-1071.
16. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of avb3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61: 1781-1785.
17. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin avb3 expression. Theranostics. 2011;1: 48-57.
18. Zhou YP, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics. 2011;1: 58-82.
19. Ye YP, Chen XY. Integrin targeting for tumor optical imaging. Theranostics. 2011;1: 102-126.
20. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all av integrins. Cell. 1998;95: 507-519.
21. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking b3 integrin or b3 and b5 integrins. Nat Med. 2002;8: 27-34.
22. Reynolds AR, Reynolds LE, Nagel TE, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in b3-integrin deficient mice. Cancer Res. 2004;64: 8643-8650.
23. Atkinson SJ, Ellison TS, Steri V, Gould E, Robinson SD. Redefining the role(s) of endothelial avb3-integrin in angiogenesis. Biochem Soc Trans. 2014;42: 1590-1595.
24. Fässler R, Meyer M. Consequences of lack of b1 integrin gene expression in mice. Genes Dev. 1995;9: 1896-1908.
25. Tanjore H, Zeisberg EM, Gerami-Naini B, Kalluri R. b1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn. 2008;237: 75-82.
26. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin a5b1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156: 1345-1362.
27. Haubner R, Maschauer S, Einsiedel J, et al. H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin a5b1? BioMed Res Int. 2014;2014: 243185.
28. Heckmann D, Laufer B, Marinelli L, et al. Breaking the dogma of the metalcoordinating carboxylate group in integrin ligands: Introducing hydroxamic acids to the MIDAS to tune potency and selectivity. Angew Chem Int Ed Engl. 2009;48: 4436-4440.
29. Rechenmacher F, Neubauer S, Polleux J, et al. Functionalizing avb3- or a5b1- selective integrin antagonists for surface coating: A method to discriminate integrin subtypes in vitro. Angew Chem Int Ed Engl. 2013;52: 1572-1575.
30. D'Alessandria C, Pohle K, Rechenmacher F, et al. In vivo biokinetic and metabolic characterization of the 68Ga-labeled a5b1-selective peptidomimetic FR366. Eur J Nucl Med Mol Imaging. October 24, 2015 [Epub ahead of print].
31. Notni J, Simecek J, Hermann P, Wester HJ. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chemistry. 2011;17: 14718-14722.
32. Notni J, Pohle K, Wester HJ. Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of 68Ga-TRAP(RGD)3. Nucl Med Biol. 2013;40: 33-41.
33. Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga-NODAGARGD is a suitable substitute for 18F-galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39: 777-784.
34. Frank AO, Otto E, Mas-Moruno C, et al. Conformational control of integrinsubtype selectivity in isoDGR peptide motifs: A biological switch. Angew Chem Int Ed Engl. 2010;49: 9278-9281.
35. Rechenmacher F, Neubauer S, Mas-Moruno C, et al. A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrinmediated cell adhesion. Chemistry. 2013;19: 9218-9223.
36. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: The first antiangiogenic small molecule drug candidate-design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10: 753-768.
37. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987;262: 17703-17711.
38. Baranyai Z, Reich D, Vágner A, et al. Shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: One-pot click chemistry trimerisation on the TRAP platform. Dalton Trans. 2015;44: 11137-11146.
39. Notni J, Pohle K, Wester HJ. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: Practical consequences for the future of gallium- 68-PET. EJNMMI Res. 2012;2: 28.
40. Poethko T, Schottelius M, Thumshirn G, et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim Acta. 2004;92: 317-327.